Revenue Increased 10% Sequentially Record Non-Prostate Brachytherapy Revenue Increased 20% Year-Over-Year RICHLAND, WASHINGTON – May 13, 2021 – Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering...
Conference Call is Thursday, May 13 at 4:30 p.m. ET/1:30 p.m. PT RICHLAND, WASHINGTON – April 29, 2021 – Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in brachytherapy powering expanding treatment options throughout the body, today...
RICHLAND, WASHINGTON – March 31, 2021 – A recently published small prospective series of patients with recurrent head and neck (H&N) cancers treated with surgical resection and Isoray’s Cesium-131 brachytherapy found potential benefits that support further...
RICHLAND, WASHINGTON – March 3, 2021 – Isoray, Inc. (NYSE American: ISR), a medical technology company and seed brachytherapy innovator, today announced that Chief Executive Officer Lori Woods will present at the Oppenheimer 31st Annual Healthcare Conference on...
RICHLAND, WASHINGTON – February 16, 2021 – Isoray, Inc. (NYSE American: ISR), a medical technology company and seed brachytherapy innovator, today announced that Lisa Lauer has been appointed Vice President, Business Development. CEO Lori Woods says Lauer’s...
Revenue Increased 7% Year-Over-Year Non-Prostate Brachytherapy Revenue Increased 92% Year-Over-Year RICHLAND, WASHINGTON – February 9, 2021 – Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding...
Conference Call is Tuesday, February 9, 2021 at 4:30 p.m. ET/1:30 p.m. PT RICHLAND, WASHINGTON – February 5, 2021– Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout the...
RICHLAND, Wash., February 4, 2021 - Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout the body, announced the pricing of its public offering of 36,000,000 shares of its...
RICHLAND, Wash., February 3, 2021 - Isoray, Inc. (NYSE AMERICAN: ISR) (“Isoray” or the “Company”), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout the body, today announced that it intends to offer and...
RICHLAND, WASHINGTON – January 7, 2021 – Isoray, Inc. (NYSE American: ISR), a medical technology company and seed brachytherapy innovator powering expanding treatment options throughout the body, today announced that Chief Executive Officer Lori Woods will present at...
HOUSTON, TEXAS - January 05, 2021 – C4 Imaging LLC is pleased to announce that Isoray Medical, Inc. (NYSE American: ISR) has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the use of C4 Imaging’s Sirius® positive-signal MRI (Magnetic Resonance...